{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:20:03Z","timestamp":1791303603780,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s00415-012-6510-x","type":"journal-article","created":{"date-parts":[[2012,5,2]],"date-time":"2012-05-02T12:30:35Z","timestamp":1335961835000},"page":"2519-2526","source":"Crossref","is-referenced-by-count":48,"title":["Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value"],"prefix":"10.1007","volume":"259","author":[{"given":"E.","family":"Zoons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. G. W.","family":"Dijkgraaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Dijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. N.","family":"van Schaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Tijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,5,3]]},"reference":[{"key":"6510_CR1","unstructured":"(2006) Literature assessment forms. http:\/\/www.cbo.nl\/thema\/Richtlijnen\/EBRO-handleiding\/G-Literatuurbeoordelings-formulieren\/"},{"key":"6510_CR2","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1136\/jnnp.72.5.608","volume":"72","author":"Y Ben-Shlomo","year":"2002","unstructured":"Ben-Shlomo Y, Camfield L, Warner T (2002) What are the determinants of quality of life in people with cervical dystonia? J Neurol Neurosurg Psychiatry 72:608\u2013614","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6510_CR3","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/WNL.46.4.1066","volume":"46","author":"JW Brans","year":"1996","unstructured":"Brans JW, Lindeboom R, Snoek JW, Zwarts MJ, van Weerden TW, Brunt ER, van Hilten JJ, van der Kamp W, Prins MH, Speelman JD (1996) Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 46:1066\u20131072","journal-title":"Neurology"},{"key":"6510_CR4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00002826-200007000-00006","volume":"23","author":"C Brefel-Courbon","year":"2000","unstructured":"Brefel-Courbon C, Simonetta-Moreau M, More C, Rascol O, Clanet M, Montastruc JL, Lapeyre-Mestre M (2000) A pharmacoeconomic evaluation of botulinum toxin in the treatment of spasmodic torticollis. Clin Neuropharmacol 23:203\u2013207","journal-title":"Clin Neuropharmacol"},{"key":"6510_CR5","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1007\/s00415-011-5998-9","volume":"258","author":"P Burbaud","year":"2011","unstructured":"Burbaud P, Ducerf C, Cugy E, Dubos JL, Muller F, Guehl D, Dehail P, Cugy D, Moore N, Lagueny A, Joseph PA (2011) Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study. J Neurol 258:1670\u20131675","journal-title":"J Neurol"},{"key":"6510_CR6","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/mds.10127","volume":"17","author":"L Camfield","year":"2002","unstructured":"Camfield L, Ben-Shlomo Y, Warner TT (2002) Impact of cervical dystonia on quality of life. Mov Disord 17:838\u2013841","journal-title":"Mov Disord"},{"key":"6510_CR7","first-page":"39","volume":"15","author":"S Chadda","year":"2009","unstructured":"Chadda S, Tilden D, Jones D, Hawthorne M, Wolf T, Sykes D (2009) Cost-effectiveness of xeominspi in the management of cervical dystonia and blepharospasm. EJHP Practice 15:39\u201346","journal-title":"EJHP Practice"},{"key":"6510_CR8","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.clinthera.2007.07.020","volume":"29","author":"MA Chapman","year":"2007","unstructured":"Chapman MA, Barron R, Tanis DC, Gill CE, Charles PD (2007) Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. Clin Ther 29:1325\u20131337","journal-title":"Clin Ther"},{"key":"6510_CR9","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/WNF.0b013e3181f5329e","volume":"33","author":"BE Crowner","year":"2010","unstructured":"Crowner BE, Torres-Russotto D, Carter AR, Racette BA (2010) Systemic weakness after therapeutic injections of botulinum toxin a: a case series and review of the literature. Clin Neuropharmacol 33:243\u2013247","journal-title":"Clin Neuropharmacol"},{"key":"6510_CR10","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2165\/00019053-199712060-00009","volume":"12","author":"RC Dodel","year":"1997","unstructured":"Dodel RC, Kirchner A, Koehne-Volland R, Kunig G, Ceballos-Baumann A, Naumann M, Brashear A, Richter HP, Szucs TD, Oertel WH (1997) Costs of treating dystonias and hemifacial spasm with botulinum toxin A. Pharmacoeconomics 12:695\u2013706","journal-title":"Pharmacoeconomics"},{"key":"6510_CR11","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s004150070094","volume":"247","author":"ESDE","year":"2000","unstructured":"ESDE (2000) A prevalence study of primary dystonia in eight European countries. J Neurol 247:787\u2013792","journal-title":"J Neurol"},{"key":"6510_CR12","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/mds.870130613","volume":"13","author":"CM Gudex","year":"1998","unstructured":"Gudex CM, Hawthorne MR, Butler AG, Duffey P (1998) Effect of dystonia and botulinum toxin treatment on health-related quality of life. Mov Disord 13:941\u2013946","journal-title":"Mov Disord"},{"key":"6510_CR13","first-page":"675","volume":"12","author":"CM Gudex","year":"1997","unstructured":"Gudex CM, Hawthorne MR, Butler AG, Duffey PO (1997) Measuring patient benefit from botulinum toxin in the treatment of dystonia. Feasibility of cost-utility analysis. Pharmacoeconomics 12:675\u2013684","journal-title":"Feasibility of cost-utility analysis. Pharmacoeconomics"},{"key":"6510_CR14","doi-asserted-by":"crossref","first-page":"622","DOI":"10.7326\/0003-4819-118-8-199304150-00009","volume":"118","author":"GH Guyatt","year":"1993","unstructured":"Guyatt GH, Feeny DH, Patrick DL (1993) Measuring health-related quality of life. Ann Intern Med 118:622\u2013629","journal-title":"Ann Intern Med"},{"key":"6510_CR15","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/archopht.124.1.116","volume":"124","author":"TA Hall","year":"2006","unstructured":"Hall TA, McGwin G Jr, Searcey K, Xie A, Hupp SL, Owsley C, Kline LB (2006) Health-related quality of life and psychosocial characteristics of patients with benign essential blepharospasm. Arch Ophthalmol 124:116\u2013119","journal-title":"Arch Ophthalmol"},{"key":"6510_CR16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/jnnp.71.2.193","volume":"71","author":"R Hilker","year":"2001","unstructured":"Hilker R, Schischniaschvili M, Ghaemi M, Jacobs A, Rudolf J (2001) Health-related quality of life is improved by botulinum neurotoxin type A in long-term treated patients with focal dystonia. J Neurol Neurosurg Psychiatry 71:193\u2013199","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl 1","key":"6510_CR17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1468-1331.2010.03059.x","volume":"17","author":"JK Krauss","year":"2010","unstructured":"Krauss JK (2010) Surgical treatment of dystonia. Eur J Neurol 17(Suppl 1):97\u2013101","journal-title":"Eur J Neurol"},{"key":"6510_CR18","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/jnnp.2005.083170","volume":"78","author":"JJ Kruisdijk","year":"2007","unstructured":"Kruisdijk JJ, Koelman JH, Ongerboer de Visser BW, de Haan RJ, Speelman JD (2007) Botulinum toxin for writer\u2019s cramp: a randomised, placebo-controlled trial and 1-year follow-up. J Neurol Neurosurg Psychiatry 78:264\u2013270","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6510_CR19","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1212\/01.WNL.0000090463.05980.59","volume":"61","author":"KD Le","year":"2003","unstructured":"Le KD, Nilsen B, Dietrichs E (2003) Prevalence of primary focal and segmental dystonia in Oslo. Neurology 61:1294\u20131296","journal-title":"Neurology"},{"key":"6510_CR20","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/mds.22838","volume":"25","author":"ED Louis","year":"2010","unstructured":"Louis ED, Ferreira JJ (2010) How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Mov Disord 25:534\u2013541","journal-title":"Mov Disord"},{"key":"6510_CR21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.parkreldis.2009.07.006","volume":"16","author":"KK Martikainen","year":"2010","unstructured":"Martikainen KK, Luukkaala TH, Marttila RJ (2010) Working capacity and cervical dystonia. Parkinsonism Relat Disord 16:215\u2013217","journal-title":"Parkinsonism Relat Disord"},{"key":"6510_CR22","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/mds.22622","volume":"24","author":"ES Molho","year":"2009","unstructured":"Molho ES, Agarwal N, Regan K, Higgins DS, Factor SA (2009) Effect of cervical dystonia on employment: a retrospective analysis of the ability of treatment to restore premorbid employment status. Mov Disord 24:1384\u20131387","journal-title":"Mov Disord"},{"key":"6510_CR23","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s00415-002-0733-1","volume":"249","author":"J Muller","year":"2002","unstructured":"Muller J, Kemmler G, Wissel J, Schneider A, Voller B, Grossmann J, Diez J, Homann N, Wenning GK, Schnider P, Poewe W (2002) The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol 249:842\u2013846","journal-title":"J Neurol"},{"key":"6510_CR24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.clineuro.2008.09.023","volume":"111","author":"T Pekmezovic","year":"2009","unstructured":"Pekmezovic T, Svetel M, Ivanovic N, Dragasevic N, Petrovic I, Tepavcevic DK, Kostic VS (2009) Quality of life in patients with focal dystonia. Clin Neurol Neurosurg 111:161\u2013164","journal-title":"Clin Neurol Neurosurg"},{"key":"6510_CR25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1524-4733.2009.00662.x","volume":"13","author":"L Shi","year":"2010","unstructured":"Shi L, Hodges M, Drummond M, Ahn J, Li SC, Hu S, Augustovski F, Hay JW, Smeeding J (2010) Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report\u2013Part VI. Value Health 13:28\u201333","journal-title":"Value Health"},{"key":"6510_CR26","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1468-1331.2007.01922.x","volume":"14","author":"IM Skogseid","year":"2007","unstructured":"Skogseid IM, Malt UF, Roislien J, Kerty E (2007) Determinants and status of quality of life after long-term botulinum toxin therapy for cervical dystonia. Eur J Neurol 14:1129\u20131137","journal-title":"Eur J Neurol"},{"key":"6510_CR27","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1002\/mds.20670","volume":"20","author":"IM Skogseid","year":"2005","unstructured":"Skogseid IM, Roislien J, Claussen B, Kerty E (2005) Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia. Mov Disord 20:1604\u20131609","journal-title":"Mov Disord"},{"key":"6510_CR28","first-page":"95","volume":"22","author":"J Slawek","year":"2007","unstructured":"Slawek J, Friedman A, Potulska A, Krystkowiak P, Gervais C, Banach M, Ochudlo S, Budrewicz S, Reclawowicz D, Rynkowski M, Opala G (2007) Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections. Funct Neurol 22:95\u2013100","journal-title":"Funct Neurol"},{"key":"6510_CR29","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1055\/s-2004-830902","volume":"24","author":"AG Smith","year":"2004","unstructured":"Smith AG (2004) Pearls and pitfalls in the therapeutic use of botulinum toxin. Semin Neurol 24:165\u2013174","journal-title":"Semin Neurol"},{"key":"6510_CR30","unstructured":"Snaith A, Wade D (2011) Dystonia. Clin Evid (Online)"},{"key":"6510_CR31","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/000348941112000708","volume":"120","author":"K Tanner","year":"2011","unstructured":"Tanner K, Roy N, Merrill RM, Sauder C, Houtz DR, Smith ME (2011) Spasmodic dysphonia: onset, course, socioemotional effects, and treatment response. Ann Otol Rhinol Laryngol 120:465\u2013473","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"6510_CR32","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMra055549","volume":"355","author":"D Tarsy","year":"2006","unstructured":"Tarsy D, Simon DK (2006) Dystonia. N Engl J Med 355:818\u2013829","journal-title":"N Engl J Med"},{"key":"6510_CR33","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1288\/00005537-199106000-00010","volume":"101","author":"DD Troung","year":"1991","unstructured":"Troung DD, Rontal M, Rolnick M, Aronson AE, Mistura K (1991) Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope 101:630\u2013634","journal-title":"Laryngoscope"},{"key":"6510_CR34","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.parkreldis.2007.11.003","volume":"14","author":"D Truong","year":"2008","unstructured":"Truong D, Comella C, Fernandez HH, Ondo WG (2008) Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord 14:407\u2013414","journal-title":"Parkinsonism Relat Disord"},{"key":"6510_CR35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1034\/j.1600-0404.2001.00109.x","volume":"103","author":"O Tucha","year":"2001","unstructured":"Tucha O, Naumann M, Berg D, Alders GL, Lange KW (2001) Quality of life in patients with blepharospasm. Acta Neurol Scand 103:49\u201352","journal-title":"Acta Neurol Scand"},{"key":"6510_CR36","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.euroneuro.2005.04.007","volume":"15","author":"S Campenhausen von","year":"2005","unstructured":"von Campenhausen S, Bornschein B, Wick R, Botzel K, Sampaio C, Poewe W, Oertel W, Siebert U, Berger K, Dodel R (2005) Prevalence and incidence of Parkinson\u2019s disease in Europe. Eur Neuropsychopharmacol 15:473\u2013490","journal-title":"Eur Neuropsychopharmacol"},{"key":"6510_CR37","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00702-010-0529-x","volume":"118","author":"B Wabbels","year":"2011","unstructured":"Wabbels B, Reichel G, Fulford-Smith A, Wright N, Roggenkamper P (2011) Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm 118:233\u2013239","journal-title":"J Neural Transm"},{"key":"6510_CR38","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1532-5415.1991.tb03623.x","volume":"39","author":"M Weinberger","year":"1991","unstructured":"Weinberger M, Samsa GP, Hanlon JT, Schmader K, Doyle ME, Cowper PA, Uttech KM, Cohen HJ, Feussner JR (1991) An evaluation of a brief health status measure in elderly veterans. J Am Geriatr Soc 39:691\u2013694","journal-title":"J Am Geriatr Soc"},{"key":"6510_CR39","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/WCO.0b013e32833b7798","volume":"23","author":"ML Welter","year":"2010","unstructured":"Welter ML, Grabli D, Vidailhet M (2010) Deep brain stimulation for hyperkinetics disorders: dystonia, tardive dyskinesia, and tics. Curr Opin Neurol 23:420\u2013425","journal-title":"Curr Opin Neurol"},{"key":"6510_CR40","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1053\/apmr.2001.21843","volume":"82","author":"J Whitaker","year":"2001","unstructured":"Whitaker J, Butler A, Semlyen JK, Barnes MP (2001) Botulinum toxin for people with dystonia treated by an outreach nurse practitioner: a comparative study between a home and a clinic treatment service. Arch Phys Med Rehabil 82:480\u2013484","journal-title":"Arch Phys Med Rehabil"},{"key":"6510_CR41","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/B978-0-12-381328-2.00021-3","volume":"98","author":"J Yianni","year":"2011","unstructured":"Yianni J, Green AL, Aziz TZ (2011) Surgical treatment of dystonia. Int Rev Neurobiol 98:573\u2013589","journal-title":"Int Rev Neurobiol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-012-6510-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T03:10:09Z","timestamp":1713928209000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-012-6510-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,3]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["6510"],"URL":"https:\/\/doi.org\/10.1007\/s00415-012-6510-x","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,3]]}}}